Compare MATX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | APGE |
|---|---|---|
| Founded | 1882 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | MATX | APGE |
|---|---|---|
| Price | $177.83 | $86.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $150.00 | $109.67 |
| AVG Volume (30 Days) | 188.1K | ★ 616.5K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $3,344,500,000.00 | N/A |
| Revenue This Year | $4.65 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $12.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.97 | $34.34 |
| 52 Week High | $180.21 | $95.32 |
| Indicator | MATX | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 55.37 |
| Support Level | $155.21 | $73.06 |
| Resistance Level | $178.22 | $95.32 |
| Average True Range (ATR) | 4.63 | 3.61 |
| MACD | -0.02 | -0.67 |
| Stochastic Oscillator | 77.16 | 36.11 |
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.